drug · small molecule
FLUTICASONE PROPIONATE
Phase 3updated 6mo agoby Paratek Pharmaceuticals Inc🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 8- tagApproval76 co-mentions · 28 sources
- drugFlonase Sensimist28 co-mentions · 14 sources
- drugFluticasone Propionate Glenmark26 co-mentions · 14 sources
- drugCutivate26 co-mentions · 14 sources
- drugFlovent26 co-mentions · 14 sources
- drugFlovent HFA26 co-mentions · 14 sources
- drugfluticasone furoate14 co-mentions · 14 sources
- companyAurobindo Pharma Ltd2 co-mentions · 2 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 14 investigational indications.
targets
Glucocorticoid receptor
all catalysts(0)
nothing on the calendar yet
Trials studying FLUTICASONE PROPIONATE
- phase3A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
- phase4Dymista in Chinese Adolescents
- phase4A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers
- phase2Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
- phase2Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
- phase3A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
- phase4Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
- phase3Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)
News(1)
- Kyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drugKyorin Pharmaceutical is paying $12 million upfront for the Japan rights to Edesa Biotech’s anti-TLR4 antibody to treat acute respiratory distress syndrome.fiercebiotech · 8d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that